|

Eganelisib Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since August 2026

Also known as: IPI-549

Pipeline

Phase 1: 2

Top Sponsors

  • Stelexis BioSciences1
  • Jacqueline Garcia, MD1

Indications

  • Cancer2
  • Leukemia, Myeloid1
  • AML, Adult1
  • Refractory Leukemia1
  • Leukemia1

Duarte, California1 trial

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

City of Hope

Phase 1

Boston, Massachusetts1 trial

Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia

Brigham and Women's Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.